Abstract:
본발명은이퀄을유효성분으로함유하는후각과민증예방또는치료용약학조성물에관한것이다. 또한, 본발명은이퀄을유효성분으로함유하는후각과민증예방또는개선용건강기능식품에관한것이다. 또한, 본발명은이퀄을함유하는악취억제용방향제조성물에관한것이다. 본발명의이퀄을함유하는조성물은후각자극에의한 cAMP의생성을억제내지감소시켜다양한후각자극물질에대해뇌에서냄새인지를못하게하는역할을한다.
Abstract:
The present invention relates to a pharmaceutical or food composition which reduces side effects, improves safety, and facilitates to stimulate enteroendocrine cells. The composition comprises Oldenlandia brachypoda extract as an effective ingredient. The composition of the present invention can be effectively used as a pharmaceutical or food composition for prevention and alleviation of diabetes, alleviation of heart diseases, alleviation or treatment of digestive disorders and malabsorption, treatment or alleviation of arteriosclerosis, neuroprotective effects, treatment or alleviation of liver diseases or the like. In addition, the composition of the present invention can promote the secretion of GLP-1, CCK or 5-HT, or the activation of hTGR5.
Abstract:
본 발명은 음나무( Kalopanax pictus ) 순 추출물 또는 분획물의 hTRPA1 활성 증가와 관련된 다양한 용도, 예를 들어 자극성 향미제, 최루제, 당뇨 또는 비만 치료제 및 hTRPA1 길항제 스크리닝에 대한 용도를 제공한다. 본 발명의 음나무순 추출물 또는 분획물은 hTRPA1 활성화와 관련된 다양한 용도를 제공하며, 천연물로서 인체에 부작용이 비교적 적고 산업적 이용 가능성이 크다. 본 발명의 음나무순 추출물 또는 분획물은 hTRPA1의 활성화와 관련된 인체내 항상성 유지에 도움이 되는 신규한 의약 또는 식품 소재일 뿐만 아니라, 최루제 등으로도 개발될 수 있으며, hTRPA1의 길항제의 스크리닝에 유용하게 이용될 수 있다.
Abstract:
The present invention provides various uses of a composition containing plant extracts from Lamiaceae, Liliaceae, or Amaranthaceae, associated with increased hTRPA1 activity; for example, use in screening pungent flavoring agents, diet pills, and hTRPA1 antagonist. The plant extracts from Lamiaceae, Liliaceae, or Amaranthaceae in the present invention provides various uses associated with hTRPA1 activation, and, being a natural compound, involves relatively few side effects in the body and has substantial industrial applicability. The plant extracts from Lamiaceae, Liliaceae, or Amaranthaceae in the present invention not only will be a novel medical or food raw material which is helpful in maintaining homeostasis in the body associated with hTRPA1 activation, but can also be used to provide an advantage in hTRPA1 antagonist screening.
Abstract:
PURPOSE: A composition containing methyl syringate for hTRPA1(human Transient Receptor Potential A1) activation is provided to screen a flavoring agent, a therapeutic agent for diabetes or obesity, and an hTRPA1 antagonist, and to be used for a pharmaceutical product or a food product. CONSTITUTION: A composition for hTRPA1 activation contains methyl syringate as an active ingredient. A Kalopanax pictus shoot extract of a Kalopanax pictus shoot fraction contains a natural compound. A method for screening an antagonist to hTRPA1 comprises: a step of treating hTRPA1 with methyl syringate and a candidate material; and a step of measuring hTRPA1 activation. A method for hTRPA1 activation comprises a step of treating a cell with methyl syringate.
Abstract:
PURPOSE: A pharmaceutical composition containing maillard peptide is provided to prevent or treat TRPV1 activation related diseases by controlling TRPV1 activation. CONSTITUTION: A pharmaceutical composition for prevnting or treating TRPV1 activation related diseases contains maillard peptides as an active ingredient, isolated from long term-matured conventional soybean sauce. The molecular weight of maillard peptides is 500-10,000. The soybean is matured more than three years.
Abstract:
본 발명은 여주에서 제조된 혈당강하용 사포닌 분획물 및 이를 포함하는 약제학적 조성물에 관한 것으로서, 여주를 수용성 에탄올로 추출하는 단계 및 부탄올 또는 흡착 수지 칼럼에 의한 분획하는 단계를 거쳐 제조되는, 혈당을 강하하는 활성을 갖는 조성물 및 이를 포함하는 약제학적 조성물로 이루어진다. 이 추출조성물 및 분획물은 혈당 강하 효과가 우수하여 공복혈당장애자, 내당능장애자, 당뇨병 전단계로 진단받은 자, 당뇨병 환자의 치료에 효과가 있다. 여주, 혈당강하, 사포닌 분획물, 당뇨 치료, 인슐린 분비 촉진 효과, 인슐린 저항성 개선 효과